Oak Associates Ltd. OH Has $418,000 Stake in United Therapeutics Corporation (UTHR)

Oak Associates Ltd. OH continued to hold its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,225 shares of the biotechnology company’s stock at the close of the second quarter. Oak Associates Ltd. OH’s holdings in United Therapeutics Corporation were worth $418,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in UTHR. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock worth $16,583,000 after purchasing an additional 2,223 shares during the period. Stifel Financial Corp increased its holdings in shares of United Therapeutics Corporation by 49.1% in the first quarter. Stifel Financial Corp now owns 3,073 shares of the biotechnology company’s stock worth $412,000 after purchasing an additional 1,012 shares during the period. Victory Capital Management Inc. increased its holdings in shares of United Therapeutics Corporation by 8.7% in the first quarter. Victory Capital Management Inc. now owns 5,416 shares of the biotechnology company’s stock worth $733,000 after purchasing an additional 432 shares during the period. Neuberger Berman Group LLC increased its holdings in shares of United Therapeutics Corporation by 22.8% in the first quarter. Neuberger Berman Group LLC now owns 4,923 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 915 shares during the period. Finally, OppenheimerFunds Inc. increased its holdings in shares of United Therapeutics Corporation by 24.8% in the first quarter. OppenheimerFunds Inc. now owns 2,881 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 573 shares during the period.

United Therapeutics Corporation (NASDAQ:UTHR) traded up 2.183% during mid-day trading on Tuesday, reaching $122.395. 68,865 shares of the company’s stock traded hands. The firm has a market cap of $5.32 billion, a price-to-earnings ratio of 14.194 and a beta of 1.50. The firm’s 50-day moving average price is $122.99 and its 200 day moving average price is $126.06. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post $10.60 EPS for the current year.

Several research analysts have recently weighed in on UTHR shares. UBS AG reaffirmed a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation presently has an average rating of “Hold” and an average target price of $132.09.

In other news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the sale, the director now directly owns 3,295 shares in the company, valued at approximately $443,111.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,263 shares of the business’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $120.20, for a total transaction of $151,812.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,323 shares of company stock worth $2,312,667. 7.80% of the stock is currently owned by insiders.

WARNING: “Oak Associates Ltd. OH Has $418,000 Stake in United Therapeutics Corporation (UTHR)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/10/17/oak-associates-ltd-oh-has-418000-stake-in-united-therapeutics-corporation-uthr.html.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit